Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
Key facts
- Who runs it
- Arrowhead Pharmaceuticals
- Where
- Ann Arbor, Greensboro, Indianapolis, Kansas City, Los Angeles, Mesquite, New Haven, New York, North Platte, Philadelphia, Pittsburgh, San Antonio, Santa Clarita, Seattle, Springfield, St Louis, and Wilmington, United StatesSee the 17 sitesAlso in 28 other countries, 119 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 288 people, planned
- Started
- 24 Apr 2025
- Expected to end
- Jun 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- Plozasiran
- Placebo
- Record updated
- 21 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Males, or nonpregnant (who do not plan to become pregnant) nonlactating females
- Established diagnosis of SHTG and prior documented evidence of fasting TG levels of ≥ 880 mg/dL (≥ 10 mmol/L)
- Documented evidence of at least 1 prior AP event not attributed to other etiologies occurring within the last 60 months prior to Screening
- Fasting low-density lipoprotein cholesterol (LDL-C) ≤ 130 mg/dL (≤ 3.37 mmol/L) at Screening
- Screening hemoglobin A1c (HbA1c) ≤ 9.5%
- Willing to follow diet counseling and maintain a stable low-fat diet
- Must be on standard of care lipid and TG-lowering medications per local guidelines (unless documented as intolerant, or a treatment failure as determined by the Investigator)
Who cannot take part
- Use of any hepatocyte-targeted small interfering ribonucleic acid (siRNA) that targets lipids and/or triglycerides within 365 days before Day 1, except inclisiran
- AP ≤ 4 weeks prior to Randomization/Day 1
- Any planned bariatric surgery or similar procedures to induce weight lost starting at consent through End of Study (EOS)
- History of pacemaker or automatic implantable cardioverter defibrillators implant within 30 days before Screening
- Planned coronary intervention (e.g. stent placement or heart bypass) during the study
- History of arterial revascularization within 16 weeks of Screening
- History of acute coronary syndrome event within 24 weeks of Screening
- Recent atherosclerotic cardiovascular disease (ASCVD) event within 24 weeks of Screening
- Recent unstable or symptomatic cardiac arrhythmia (including any associated medication changes) within 90 days of Screening. Individuals with stable well-controlled atrial arrhythmia will be allowed to participate in the study
- Current diagnosis of nephrotic syndrome
- New York Heart Association Class III-IV heart failure or last known ejection fraction of < 30%
- Chronic kidney disease, defined by an estimated glomerular filtration rate (eGFR) < 20 mL/min/1.73 m\^2
- Liver disease defined as cirrhosis or Child-Pugh Class B and C, or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5× Upper Limit of Normal (ULN) at Screening; Note: Additional Inclusion/Exclusion Criteria may apply per protocol
- Use of any other hepatocyte targeted siRNA or antisense oligonucleotide molecule within 60 days or within 5 half-lives lives before day 1. Whichever is longer
- Body mass index (BMI) > 45 kg/m\^2
Where in United States
Also in 28 other countries, 119 sites
- Ann Arbor, MichiganHospital not named in the registryContact: Medical MonitorTaking people
- Greensboro, North CarolinaHospital not named in the registryContact: Medical MonitorTaking people
- Indianapolis, IndianaHospital not named in the registryContact: Medical MonitorTaking people
- Kansas City, MissouriHospital not named in the registryContact: Medical MonitorTaking people
- Los Angeles, CaliforniaHospital not named in the registryContact: Medical MonitorTaking people
- Mesquite, TexasHospital not named in the registryContact: Medical MonitorTaking people
- New Haven, ConnecticutHospital not named in the registryContact: Medical MonitorTaking people
- New YorkHospital not named in the registryContact: Medical MonitorTaking people
- North Platte, NebraskaHospital not named in the registryContact: Medical MonitorTaking people
- Philadelphia, PennsylvaniaHospital not named in the registryContact: Medical MonitorTaking people
- Pittsburgh, PennsylvaniaHospital not named in the registryContact: Medical MonitorTaking people
- San Antonio, TexasHospital not named in the registryContact: Medical MonitorTaking people
- Santa Clarita, CaliforniaHospital not named in the registryContact: Medical MonitorTaking people
- Seattle, WashingtonHospital not named in the registryContact: Medical MonitorTaking people
- Springfield, IllinoisHospital not named in the registryContact: Medical MonitorTaking people
- St Louis, MissouriHospital not named in the registryContact: Medical MonitorTaking people
- Wilmington, North CarolinaHospital not named in the registryContact: Medical MonitorTaking people
About the trial
What the trial wants to find out
This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to other etiologies, with at least one occurring within the last 12 months prior to screening. Eligible participants will be randomly assigned in a double-blind manner to either receive plozasiran 25 mg by subcutaneous (SC) injection every three months (Q3M) or matching placebo. Enrolled participants will be counseled to remain on the specified low-fat diet and background medications throughout the study. Following completion of the double-blind treatment period, or if the participant has a positively adjudicated AP event (whichever occurs first), participants will transition to the 12-month Open-Label Extension (OLE) treatment period receiving plozasiran 25 mg by SC injection Q3M.
The 2 groups in the trial
- Plozasiran InjectionTreatment being tested
Plozasiran by SC injection every 3 months (Q3M) through completion of the randomized period Plozasiran by SC injection Q3M through completion of the OLE period
Treatment: Plozasiran
- PlaceboTreatment being tested
calculated volume to match active treatment by SC injection (randomized period)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)
- Record updated
- 21 September 2026